Equities researchers at Jefferies Financial Group began coverage on shares of Santen Pharmaceutical (OTCMKTS:SNPHY) in a report issued on Monday, The Fly reports. The brokerage set a “hold” rating on the stock.
Shares of OTCMKTS SNPHY opened at $18.99 on Monday.
About Santen Pharmaceutical
Santen Pharmaceutical Co, Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-126 that is in Phase 2b clinical trial; DE-128, which is in Phase 2/3 clinical trial; DE-130A that is in Phase III clinical trial; and DE-117.
Recommended Story: How big is the FinTech market?
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.